|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
|
US6630584B1
(en)
|
2000-03-16 |
2003-10-07 |
Ramot At Tel-Aviv University Ltd. |
Single chain antibody against mutant p53
|
|
AU2003216341A1
(en)
|
2002-02-20 |
2003-09-09 |
Dyax Corporation |
Mhc-peptide complex binding ligands
|
|
JP3738308B2
(ja)
|
2002-11-29 |
2006-01-25 |
篤 村口 |
抗原特異的リンパ球抗原受容体遺伝子のクローニング方法
|
|
MXPA05014155A
(es)
|
2003-06-27 |
2006-05-25 |
Abgenix Inc |
Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
|
|
WO2005099361A2
(en)
|
2003-07-10 |
2005-10-27 |
Vaccinex, Inc. |
MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
|
|
EP1712620A4
(en)
|
2004-01-23 |
2008-05-28 |
Greenpeptide Co Ltd |
EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
|
|
US20060034850A1
(en)
|
2004-05-27 |
2006-02-16 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
SG188175A1
(en)
|
2004-06-03 |
2013-03-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
|
WO2006100681A2
(en)
|
2005-03-25 |
2006-09-28 |
Ramot At Tel Aviv University Ltd. |
Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
|
|
CN101228187A
(zh)
|
2005-03-25 |
2008-07-23 |
特拉维夫大学拉莫特有限公司 |
针对突变p53的共同表位的人合成单链抗体及其用途
|
|
AU2006291005A1
(en)
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-CD3 antibody formulations
|
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン,エルエルシー |
EphA2BiTE分子およびその使用
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EA201401134A1
(ru)
|
2011-02-11 |
2015-05-29 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
|
|
WO2012162067A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
CN104203981A
(zh)
|
2011-12-19 |
2014-12-10 |
合成免疫股份有限公司 |
双特异性抗体分子
|
|
IL298125A
(en)
|
2013-02-26 |
2023-01-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
ES2765710T3
(es)
|
2014-04-03 |
2020-06-10 |
Cellectis |
Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
|
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
|
SG10201913978RA
(en)
|
2014-11-26 |
2020-03-30 |
The United States Of America As Represented By The Secretary |
Anti-mutated kras t cell receptors
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
EP3286222A4
(en)
*
|
2015-03-23 |
2018-08-08 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
JP6913032B2
(ja)
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
IL281396B
(en)
|
2015-06-09 |
2022-07-01 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
SG10201913868XA
(en)
|
2015-09-15 |
2020-03-30 |
The United States Of America As Represented By The Secretary |
T cell receptors recognizing hla-cw8 restricted mutated kras
|
|
AR107582A1
(es)
|
2016-02-03 |
2018-05-16 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
|
CA3034093A1
(en)
|
2016-08-23 |
2018-03-01 |
The Regents Of The University Of California |
Proteolytically cleavable chimeric polypeptides and methods of use thereof
|
|
US20190240257A1
(en)
|
2016-10-13 |
2019-08-08 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
GB201617564D0
(en)
*
|
2016-10-17 |
2016-11-30 |
Agency For Science Technology And Research And National University Of Singapore And Singapore Health |
Anti-p53 antibodies
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
EP3599250A4
(en)
*
|
2017-01-24 |
2021-06-09 |
Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. |
ANTIBODY CONJUGATE AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
|
|
US20200325244A1
(en)
|
2020-05-18 |
2020-10-15 |
Abexxa Biologics, Inc. |
Antibodies and methods of use thereof
|
|
US11807662B2
(en)
|
2017-05-16 |
2023-11-07 |
The Johns Hopkins University |
MANAbodies and methods of using
|
|
JP7391015B2
(ja)
|
2017-09-29 |
2023-12-04 |
アメリカ合衆国 |
P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法
|
|
MX2020005765A
(es)
|
2017-12-04 |
2020-09-25 |
Us Health |
Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
|
|
EP3755802A4
(en)
*
|
2018-02-21 |
2021-11-17 |
Singapore Health Services Pte Ltd |
THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS
|
|
WO2021127184A1
(en)
|
2019-12-17 |
2021-06-24 |
The Johns Hopkins University |
MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
|
|
WO2021127814A1
(zh)
|
2019-12-23 |
2021-07-01 |
深圳市人民医院 |
用于癌症治疗的光纳米疫苗及其制备方法和应用
|
|
WO2022212682A2
(en)
|
2021-03-31 |
2022-10-06 |
The Johns Hopkins University |
Methods and materials for targeting tumor antigens
|
|
US20250034252A1
(en)
|
2021-12-16 |
2025-01-30 |
The Johns Hopkins University |
Manabodies targeting p53 tumor antigens and methods of using
|